Investigators report that adoptive T cell transfer (ACT) therapy, using CD4 T cells expressing elevated levels of the protein CD26, effectively regresses solid tumors. CD8 T cells are more commonly used for ACT therapy, because they are thought to be better cancer fighters. However, this study showed that CD4 T cells, expressing high CD26, resist death and are robustly effective at killing multiple tumor types.